KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Operating Expenses (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Other Operating Expenses for 15 consecutive years, with $65.3 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 46.07% to $65.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $189.4 million through Dec 2025, up 26.48% year-over-year, with the annual reading at $189.4 million for FY2025, 26.48% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $65.3 million at Supernus Pharmaceuticals, up from $43.3 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $65.3 million in Q4 2025, with the low at $22.2 million in Q2 2021.
  • Average Other Operating Expenses over 5 years is $40.6 million, with a median of $41.3 million recorded in 2021.
  • The sharpest move saw Other Operating Expenses soared 662.26% in 2021, then fell 26.34% in 2024.
  • Over 5 years, Other Operating Expenses stood at $30.1 million in 2021, then surged by 36.86% to $41.2 million in 2022, then skyrocketed by 47.11% to $60.7 million in 2023, then dropped by 26.34% to $44.7 million in 2024, then soared by 46.07% to $65.3 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $65.3 million, $43.3 million, and $37.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.